c6396737-3587-46a7-808d-963eebe41224
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 76.9856262833676
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.580
- ANGIOGENESIS+0.550
- ALLOGRAFT_REJECTION+0.530
- IL6_JAK_STAT3_SIGNALING+0.530
- INFLAMMATORY_RESPONSE+0.510
- INTERFERON_GAMMA_RESPONSE+0.490
- TNFA_SIGNALING_VIA_NFKB+0.480
- INTERFERON_ALPHA_RESPONSE+0.450
- COMPLEMENT+0.430
- MYOGENESIS+0.430
Top 10 suppressed
- E2F_TARGETS-0.550
- G2M_CHECKPOINT-0.530
- MYC_TARGETS_V1-0.480
- MYC_TARGETS_V2-0.460
- OXIDATIVE_PHOSPHORYLATION-0.460
- MITOTIC_SPINDLE-0.350
- GLYCOLYSIS-0.290
- FATTY_ACID_METABOLISM-0.280
- PEROXISOME-0.280
- DNA_REPAIR-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-77-A5FZ-01A-31R-A27Q-07 | — | cohortMD2 | 0.937 |
| 2 | SRR22247245 | — | cohortMD2 | 0.934 |
| 3 | ERR2208937 | — | — | 0.932 |
| 4 | SRR17866819 | — | — | 0.930 |
| 5 | C3N-02923 | — | cohortMD2 | 0.929 |
| 6 | TCGA-CX-7085-01A-21R-2016-07 | — | — | 0.922 |
| 7 | 2cec663c-00c8-48b5-967b-f2a53c0fb409 | — | — | 0.922 |
| 8 | TCGA-A2-A0EN-01A-13R-A084-07 | — | A | 0.921 |
| 9 | TCGA-XF-AAN4-01A-11R-A42T-07 | — | — | 0.920 |
| 10 | MDT-AP-3277 | Med | Medulloblastoma | 0.920 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.580 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.550 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.530 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.530 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.510 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.490 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.480 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.450 | Inavolisib | — uncovered |
| COMPLEMENT | 0.430 | Inavolisib | — uncovered |
| MYOGENESIS | 0.430 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.360 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.350 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.340 | Inavolisib | — uncovered |
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| HYPOXIA | 0.270 | Idelalisib | — uncovered |
| APOPTOSIS | 0.230 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.210 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.150 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.150 | Remibrutinib | — uncovered |